Abstract
Excessive daytime sleepiness (EDS) is one of the symptoms that could accompany central nervous system disorders. EDS is the primary complaint in narcolepsy with cataplexy, narcolepsy without cataplexy, recurrent hypersomnia, idiopathic hypersomnia with long sleep time and idiopathic hypersomnia without long sleep time, diseases forming a group named hypersomnias of central origin. Pathophysiology, based on hypocretin neurons loss hypothesis, is known only in narcolepsy with cataplexy. That is why causal therapy does not exist for central hypersomnias EDS. The only available treatment is based on stimulants (and on sodium oxybate in narcolepsy). Sleep-related movement disorders (restless legs syndrome and periodic limb movements in sleep) affect the quality of sleep and in certain patients develops into EDS. Sleepiness is frequently reported in Parkinson’s disease, traumatic brain injury, myotonic dystrophy, in stroke, and others. Treatment of EDS in these neurologic conditions is not well documented, but stimulants seem to be partially effective. This chapter provides more detailed view of symptoms, pathophysiology, and treatment of these conditions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Academy of Sleep Medicine (2005) The international classification of sleep disorders: diagnostic and coding manual, 2nd edn. American Academy of Sleep Medicine, Westchester
American Academy of Sleep Medicine (2005) Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28:113–121
Mignot E, Lammers GJ, Ripley B et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553–1562
Mignot E, Hayduk R, Black J et al (1997) HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20:1012–1020
Lecendreux M, Maret S, Bassetti C et al (2003) Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 12:347–348
Hallmayer J, Faraco J, Lin L et al (2009) Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41:708–711
Aran A, Lin L, Nevsimalova S et al (2009) Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32:979–983
Cvetkovic-Lopes V, Bayer L, Dorsaz S et al (2010) Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 120:713–719
Nohynek H, Jokinen J, Partinen M (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7:e33536
Longstreth WT Jr, Koepsell TD, Ton TG et al (2007) The epidemiology of narcolepsy. Sleep 30:13–26
Yoss RE, Daly DD (1960) Narcolepsy in children. Pediatrics 25:1025–1033
Billiard M, Bassetti C, Dauvilliers Y et al (2006) EFNS guidelines on management of narcolepsy. Eur J Neurol 13:1035–1048
Morgenthaler TI, Kapur VK, Brown T et al (2007) Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30:1705–1711
Wise MS, Arand DL, Auger RR et al (2007) Treatment of narcolepsy and other hypersomnias of central origin. Sleep 30:1712–1727
Lecendreux M, Bruni O, Franco P et al (2012) Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res 21:481–483
Dauvilliers Y, Bassetti C, Lammers GJ et al (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomized trial. Lancet Neurol 12:1068–1075
Boscolo-Berto R, Viel G, Montagnese S et al (2012) Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 16:431–443
Vernet C, Arnulf I (2009) Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. Sleep 32:753–759
Arnulf I, Rico TJ, Mignot E (2012) Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. Lancet Neurol 11:918–928
Rye DB (2011) Parkinson’s disease and sleepiness. In: Thorpy MJ, Billiard M (eds) Sleepiness: causes, consequences, and treatment. Cambridge University Press, Cambridge, pp 301–315
Laberge L, Dauvilliers Y (2011) Myotonic distrophy and sleepiness. In: Thorpy MJ, Billiard M (eds) Sleepiness: causes, consequences, and treatment. Cambridge University Press, Cambridge, pp 316–328
Baumann CR, Bassetti CL, Valko PO et al (2009) Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol 66:555–559
Kanbayashi T, Shimohata T, Nakashima I et al (2009) Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 66:1563–1566
Acknowledgments
Preparation of this chapter was supported by the Czech Ministry of Health grant NT13238-4/2012 and Charles University grant PRVOUK –P26/LF1/4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Šonka, K., Susta, M. (2014). Neurologic Disorders. In: Garbarino, S., Nobili, L., Costa, G. (eds) Sleepiness and Human Impact Assessment. Springer, Milano. https://doi.org/10.1007/978-88-470-5388-5_23
Download citation
DOI: https://doi.org/10.1007/978-88-470-5388-5_23
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5387-8
Online ISBN: 978-88-470-5388-5
eBook Packages: MedicineMedicine (R0)